1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Deltex Medical Group plc

Deltex Medical Group plc

DEMG.L
Deltex Medical Group plcGB flagLondon Stock Exchange
0.02
GBp
-0.01
- -
663,609.00Market Cap
Deltex Medical Group plc
DEMG.L
(London Stock Exchange)

Recent

price

0.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
FRC
0.05
0.05
0.05
0.05
0.05
0.04
0.03
0.03
0.02
0.02
0.01
0.01
- -
- -
- -
- -
Revenue per Share
-0.03
-0.02
-0.01
-0.01
-0.01
-0.01
-0.02
-0.02
-0.01
-0.01
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.03
-0.02
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.38
-0.36
-0.3
-0.3
-0.29
-0.27
-0.24
-0.23
-0.19
-0.18
-0.1
-0.1
-0.09
-0.09
-0.07
-0.04
Book Value per Share
0.01
0.01
- -
0.01
0.01
0.01
0.02
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
97
105
130
137
148
164
195
217
270
301
471
510
526
581
685
1,181
Basic Weighted Avg Shares
5
6
6
6
7
7
7
6
6
6
5
4
2
2
2
2
Sales/Revenue/Turnover
-51.04
-24.96
-20.8
-22.24
-30.66
-29.34
-45.95
-52.04
-37.42
-32.91
-21.33
2.37
-38.53
-38.16
-39.44
-48.31
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-3
-2
-1
-1
-2
-2
-3
-3
-2
-2
-1
- -
-1
-1
-1
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-48.84
-35.25
-23.38
-22.54
-30.88
-29.45
-45.35
-54.02
-37.53
-34.09
-25.51
-3.74
-32.74
-42.76
-46.17
-72.18
Profit Margin (%)
1
2
1
2
2
2
4
-1
1
- -
1
1
1
- -
- -
1
Working Capital
- -
1
1
1
1
1
1
- -
1
1
1
1
1
1
1
2
LT Debt
1
2
1
2
2
3
5
2
2
1
2
3
3
2
2
3
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.78%
8.22%
41.07%
Free Cash Flow
26.45%
54.8%
78.11%
Net Income, GAAP
33.33%
71.97%
11.87%
Sales/Revenue/Turnover
-11.67%
-16.43%
-28.44%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
2
2022
- -
- -
- -
- -
2
2023
- -
- -
- -
- -
2

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
UFP Technologies, Inc. (UFPT)
Bonesupport Holding AB (publ) (BOEUF)
Titan Medical Inc. (TMD.TO)
Demant A/S (DEMANT.CO)
Xvivo Perfusion AB (publ) (XVIPY)
Drägerwerk AG & Co. KGaA (DWRKF)
Business
Deltex Medical Group plc (DEMG.L) manufactures and markets advanced haemodynamic monitoring systems for surgical and critical care applications; its core offerings include the TrueVue platform featuring Oesophageal Doppler Monitoring (ODM+), CardioQ-EDM and CardioQ-EDM+ probes for real-time blood flow measurement in the descending aorta, pulse contour analysis tools, and complementary non-invasive Doppler-based technologies; single-use disposable ODM probes drive recurring revenues alongside monitor sales or loans. The company targets anaesthetists and clinicians managing fluid and drug administration to minimise postoperative complications such as acute kidney injury and surgical site infections, with products endorsed by NICE as a High Impact Innovation and supported by over 24 randomised controlled trials demonstrating reduced length of hospital stay and cost savings. Deltex Medical Group plc operates from its headquarters and manufacturing facility in Chichester, West Sussex, United Kingdom, with subsidiaries in the USA, Canada, and Spain, and distribution across more than 30 countries including recent tender pursuits in Latin America. Founded in 2000 and listed on the London Stock Exchange AIM market, the company manufactures medical instruments under SIC code 32500 and maintains over 3,000 ODM systems in global use. In November 2023, Deltex Medical Group plc launched its next-generation TrueVue monitor, incorporating enhanced ODM signal acquisition, intuitive HD touchscreen controls, integrated battery for portability, and extensions to non-invasive monitoring developed in collaboration with the UK's National Physical Laboratory, substantially expanding addressable markets to non-sedated patients in critical care and throughout hospitals; the US launch of TrueVue followed, alongside implementation of zero-based budgeting and digital marketing efficiencies post-2023 fundraising to support commercial growth; ongoing development includes lower-cost non-invasive devices compatible with TrueVue, positioning ODM as a standard for elective surgery and intensive care.